Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
Last Updated: Wednesday, November 22, 2023
According to data from a phase 2, open-label trial among patients with untreated DLBCL, mosunetuzumab plus CHOP demonstrates promising activity and a manageable toxicity profile. With a median follow-up of 32.0 months, the estimated 2-year PFS and EFS rates were 65.4% and 60.4%, respectively.
Advertisement
News & Literature Highlights
